Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4032)	12/21/2015 6:10:42 PM
From: mulanoon2007	Read Replies (1) \| Respond to of 4474

In December's Haematologica, MD Anderson show a little more love in their love-hate relationship with PON. Only 5 pts were enrolled in their "second line" phase 2 (before FDA safety concern) which evaluated PON following failure of IMA (n=3) or DAS (n=2). At median of 3 months, pts began receiving lower doses of PON (3 pts received 30 mg, 2 pts received 15 mg). After a median follow up of 22 months, cumulative best response for all patients was PCyR in one pt and MR4.5 in 4 pts. No thrombosis was reported. Authors' state "Importantly, it is apparent from our results that patients can have sustained responses on lower doses of ponatinib, and the toxicity profile of ponatinib was manageable at these doses in our group." haematologica.org